|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
|
|
2
|
Reungwetwattana T, Weroha SJ and Molina
JR: Oncogenic pathways, molecularly targeted therapies, and
highlighted clinical trials in non-small-cell lung cancer (NSCLC).
Clin Lung Cancer. 13:252–266. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Schiller JH: Small cell lung cancer:
defining a role for emerging platinum drugs. Oncology. 63:105–114.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Stinchcombe TE and Socinski MA: Treatment
paradigms for advanced stage non-small cell lung cancer in the era
of multiple lines of therapy. J Thorac Oncol. 4:243–250. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ramalingam S and Belani CP: Recent
advances in targeted therapy for non-small cell lung cancer. Expert
Opin Ther Targets. 11:245–257. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang Y, Ni J, Zhou G, et al: Cloning,
expression and characterization of the human NOB1 gene. Mol
Biol Rep. 32:185–189. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Makarova KS, Aravind L, Galperin MY, et
al: Comparative genomics of the Archaea (Euryarchaeota): evolution
of conserved protein families, the stable core, and the variable
shell. Genome Res. 9:608–628. 1999.PubMed/NCBI
|
|
8
|
Arcus VL, Backbro K, Roos A, Daniel EL and
Baker EN: Distant structural homology leads to the functional
characterization of an archaeal PIN domain as an exonuclease. J
Biol Chem. 279:16471–16478. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lamanna AC and Karbstein K: Nob1 binds the
single-stranded cleavage site D at the 3′-end of 18S rRNA with its
PIN domain. Proc Natl Acad Sci USA. 106:14259–14264.
2009.PubMed/NCBI
|
|
10
|
Fatica A, Tollervey D and Dlakic M: PIN
domain of Nob1p is required for D-site cleavage in 20S pre-rRNA.
RNA. 10:1698–1701. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fatica A, Oeffinger M, Dlakic M and
Tollervey D: Nob1p is required for cleavage of the 3′ end of 18S
rRNA. Mol Cell Biol. 23:1798–1807. 2003.
|
|
12
|
Huang WY, Chen DH, Ning L and Wang LW:
siRNA mediated silencing of NIN1/RPN12 binding protein 1 homolog
inhibits proliferation and growth of breast cancer cells. Asian Pac
J Cancer Prev. 13:1823–1827. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lu Z, Guo Q, Shi A, Xie F and Lu Q:
Downregulation of NIN/RPN12 binding protein inhibits the growth of
human hepatocellular carcinoma cells. Mol Biol Rep. 39:501–507.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lin Y, Peng S, Yu H, Teng H and Cui M:
RNAi-mediated downregulation of NOB1 suppresses the growth
and colony-formation ability of human ovarian cancer cells. Med
Oncol. 29:311–317. 2012.
|
|
15
|
Wu DP and He XW: Expression of NOB1 and
its significance in colorectal cancer. Nan Fang Yi Ke Da Xue Xue
Bao. 32:420–422. 2012.(in Chinese).
|
|
16
|
Lin S, Meng W, Zhang W, et al: Expression
of the NOB1 gene and its clinical significance in papillary
thyroid carcinoma. J Int Med Res. 41:568–572. 2013.
|
|
17
|
Oehler VG, Yeung KY, Choi YE, Bumgarner
RE, Raftery AE and Radich JP: The derivation of diagnostic markers
of chronic myeloid leukemia progression from microarray data.
Blood. 114:3292–3298. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Granneman S, Nandineni MR and Baserga SJ:
The putative NTPase Fap7 mediates cytoplasmic 20S pre-rRNA
processing through a direct interaction with Rps14. Mol Cell Biol.
25:10352–10364. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ramos PC, Hockendorff J, Johnson ES,
Varshavsky A and Dohmen RJ: Ump1p is required for proper maturation
of the 20S proteasome and becomes its substrate upon completion of
the assembly. Cell. 92:489–499. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Raychaudhuri S, Fontanes V, Barat B and
Dasgupta A: Activation of ribosomal RNA transcription by hepatitis
C virus involves upstream binding factor phosphorylation via
induction of cyclin D1. Cancer Res. 69:2057–2064. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Meraner J, Lechner M, Loidl A, et al:
Acetylation of UBF changes during the cell cycle and regulates the
interaction of UBF with RNA polymerase I. Nucleic Acids Res.
34:1798–1806. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shirane M, Harumiya Y, Ishida N, et al:
Down-regulation of p27Kip1 by two mechanisms,
ubiquitin-mediated degradation and proteolytic processing. J Biol
Chem. 274:13886–13893. 1999.PubMed/NCBI
|
|
23
|
Xu G, Bernaudo S, Fu G, Lee DY, Yang BB
and Peng C: Cyclin G2 is degraded through the ubiquitin-proteasome
pathway and mediates the antiproliferative effect of activin
receptor-like kinase 7. Mol Biol Cell. 19:4968–4979. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fasanaro P, Capogrossi MC and Martelli F:
Regulation of the endothelial cell cycle by the
ubiquitin-proteasome system. Cardiovasc Res. 85:272–280. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Niculescu AB III, Chen X, Smeets M, Hengst
L, Prives C and Reed SI: Effects of p21Cip1/Waf1 at both
the G1/S and the G2/M cell cycle transitions:
pRb is a critical determinant in blocking DNA replication and in
preventing endoreduplication. Mol Cell Biol. 18:629–643. 1998.
|
|
26
|
Gu Y, Turck CW and Morgan DO: Inhibition
of CDK2 activity in vivo by an associated 20K regulatory
subunit. Nature. 366:707–710. 1993.PubMed/NCBI
|
|
27
|
Harper JW, Adami GR, Wei N, Keyomarsi K
and Elledge SJ: The p21 Cdk-interacting protein Cip1 is a potent
inhibitor of G1 cyclin-dependent kinases. Cell. 75:805–816. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cai K and Dynlacht BD: Activity and nature
of p21WAF1 complexes during the cell cycle. Proc Natl
Acad Sci USA. 95:12254–12259. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ogryzko VV, Wong P and Howard BH: WAF1
retards S-phase progression primarily by inhibition of
cyclin-dependent kinases. Mol Cell Biol. 17:4877–4882.
1997.PubMed/NCBI
|
